Variable clinical symptoms in familial amyotrophic lateral sclerosis with a novel point mutation in the Cu/Zn superoxide dismutase gene

M. Ikeda, Koji Abe, M. Aoki, M. Sahara, M. Watanabe, M. Shoji, P. H. St. George-Hyslop, S. Hirai, Y. Itoyama

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

We report a novel missense point mutation in exon 4 of the Cu/Zn superoxide dismutase (SOD) gene of affected members of a Japanese kindred segregating familial amyotrophic lateral sclerosis (FALS) through at least three successive generations. The mutation, which is predicted to cause the replacement of isoleucine at codon 104 by phenylalanine (I104F), is associated with a significant reduction in Cu/Zn SOD enzyme activity but results in a highly variable clinical phenotype. Age at onset varied from 6 to 55; the initial symptoms occurred in either the lower or upper extremities in different family members. The duration of the disease varied from 3 to 38 years. Two subjects, aged 59 and 34, remained asymptomatic until their death from other causes, although their offspring carrying the same mutation have already developed clinical evidence of the disease. These results suggest that FALS from this novel I104F mutation shows considerable clinical variation.

Original languageEnglish
Pages (from-to)2038-2042
Number of pages5
JournalNeurology
Volume45
Issue number11
Publication statusPublished - 1995
Externally publishedYes

Fingerprint

Point Mutation
Mutation
Genes
Isoleucine
Missense Mutation
Phenylalanine
Age of Onset
Upper Extremity
Codon
Cause of Death
Exons
Phenotype
Enzymes
Superoxide Dismutase-1
Amyotrophic lateral sclerosis 1
Amyotrophic Lateral Sclerosis
Gene
Familial
Causes

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Ikeda, M., Abe, K., Aoki, M., Sahara, M., Watanabe, M., Shoji, M., ... Itoyama, Y. (1995). Variable clinical symptoms in familial amyotrophic lateral sclerosis with a novel point mutation in the Cu/Zn superoxide dismutase gene. Neurology, 45(11), 2038-2042.

Variable clinical symptoms in familial amyotrophic lateral sclerosis with a novel point mutation in the Cu/Zn superoxide dismutase gene. / Ikeda, M.; Abe, Koji; Aoki, M.; Sahara, M.; Watanabe, M.; Shoji, M.; St. George-Hyslop, P. H.; Hirai, S.; Itoyama, Y.

In: Neurology, Vol. 45, No. 11, 1995, p. 2038-2042.

Research output: Contribution to journalArticle

Ikeda, M, Abe, K, Aoki, M, Sahara, M, Watanabe, M, Shoji, M, St. George-Hyslop, PH, Hirai, S & Itoyama, Y 1995, 'Variable clinical symptoms in familial amyotrophic lateral sclerosis with a novel point mutation in the Cu/Zn superoxide dismutase gene', Neurology, vol. 45, no. 11, pp. 2038-2042.
Ikeda, M. ; Abe, Koji ; Aoki, M. ; Sahara, M. ; Watanabe, M. ; Shoji, M. ; St. George-Hyslop, P. H. ; Hirai, S. ; Itoyama, Y. / Variable clinical symptoms in familial amyotrophic lateral sclerosis with a novel point mutation in the Cu/Zn superoxide dismutase gene. In: Neurology. 1995 ; Vol. 45, No. 11. pp. 2038-2042.
@article{8e81b96d4a534772bb14056474fc5bf0,
title = "Variable clinical symptoms in familial amyotrophic lateral sclerosis with a novel point mutation in the Cu/Zn superoxide dismutase gene",
abstract = "We report a novel missense point mutation in exon 4 of the Cu/Zn superoxide dismutase (SOD) gene of affected members of a Japanese kindred segregating familial amyotrophic lateral sclerosis (FALS) through at least three successive generations. The mutation, which is predicted to cause the replacement of isoleucine at codon 104 by phenylalanine (I104F), is associated with a significant reduction in Cu/Zn SOD enzyme activity but results in a highly variable clinical phenotype. Age at onset varied from 6 to 55; the initial symptoms occurred in either the lower or upper extremities in different family members. The duration of the disease varied from 3 to 38 years. Two subjects, aged 59 and 34, remained asymptomatic until their death from other causes, although their offspring carrying the same mutation have already developed clinical evidence of the disease. These results suggest that FALS from this novel I104F mutation shows considerable clinical variation.",
author = "M. Ikeda and Koji Abe and M. Aoki and M. Sahara and M. Watanabe and M. Shoji and {St. George-Hyslop}, {P. H.} and S. Hirai and Y. Itoyama",
year = "1995",
language = "English",
volume = "45",
pages = "2038--2042",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Variable clinical symptoms in familial amyotrophic lateral sclerosis with a novel point mutation in the Cu/Zn superoxide dismutase gene

AU - Ikeda, M.

AU - Abe, Koji

AU - Aoki, M.

AU - Sahara, M.

AU - Watanabe, M.

AU - Shoji, M.

AU - St. George-Hyslop, P. H.

AU - Hirai, S.

AU - Itoyama, Y.

PY - 1995

Y1 - 1995

N2 - We report a novel missense point mutation in exon 4 of the Cu/Zn superoxide dismutase (SOD) gene of affected members of a Japanese kindred segregating familial amyotrophic lateral sclerosis (FALS) through at least three successive generations. The mutation, which is predicted to cause the replacement of isoleucine at codon 104 by phenylalanine (I104F), is associated with a significant reduction in Cu/Zn SOD enzyme activity but results in a highly variable clinical phenotype. Age at onset varied from 6 to 55; the initial symptoms occurred in either the lower or upper extremities in different family members. The duration of the disease varied from 3 to 38 years. Two subjects, aged 59 and 34, remained asymptomatic until their death from other causes, although their offspring carrying the same mutation have already developed clinical evidence of the disease. These results suggest that FALS from this novel I104F mutation shows considerable clinical variation.

AB - We report a novel missense point mutation in exon 4 of the Cu/Zn superoxide dismutase (SOD) gene of affected members of a Japanese kindred segregating familial amyotrophic lateral sclerosis (FALS) through at least three successive generations. The mutation, which is predicted to cause the replacement of isoleucine at codon 104 by phenylalanine (I104F), is associated with a significant reduction in Cu/Zn SOD enzyme activity but results in a highly variable clinical phenotype. Age at onset varied from 6 to 55; the initial symptoms occurred in either the lower or upper extremities in different family members. The duration of the disease varied from 3 to 38 years. Two subjects, aged 59 and 34, remained asymptomatic until their death from other causes, although their offspring carrying the same mutation have already developed clinical evidence of the disease. These results suggest that FALS from this novel I104F mutation shows considerable clinical variation.

UR - http://www.scopus.com/inward/record.url?scp=0029400840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029400840&partnerID=8YFLogxK

M3 - Article

C2 - 7501156

AN - SCOPUS:0029400840

VL - 45

SP - 2038

EP - 2042

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 11

ER -